Search Results - "Szmulewitz, R Z"

Playing Russian Roulette With Tyrosine Kinase Inhibitors by Szmulewitz, R Z, Ratain, M J

“…With the advent of molecularly “targeted therapies,” most notably the tyrosine kinase inhibitors (TKIs), there has been a significant shift in our formulary…”
Get full text

Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate by Weiner, A B, Patel, S G, Richards, K A, Szmulewitz, R Z, Eggener, S E

“…Background: Small-cell carcinoma of the prostate is an aggressive cancer whose rarity has prevented the development of a consensus management approach. The…”
Get full text

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium Department of Defense Prostate Cancer Clinical Trials Consortium study by Ward, J E, Karrison, T, Chatta, G, Hussain, M, Shevrin, D, Szmulewitz, R Z, O'Donnell, P H, Stadler, W M, Posadas, E M

“…Background: Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of…”
Get full text

853PARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups by Stenzl, A, Szmulewitz, R Z, Petrylak, D P, Holzbeierlein, J, Villers, A, Azad, A A, Alcaraz, A, Alekseev, B Y, Iguchi, T, Shore, N D, Rosbrook, B, Baron, B, Haas, G P, Morlock, R, Ramaswamy, K, Armstrong, A J

“…Abstract Background ENZA, a potent androgen receptor inhibitor, provides benefit in men with castration-resistant prostate cancer (CRPC). In post hoc analyses,…”
Get full text

Fluorescence-activated cell sorting (FACS) and immunofluorescence (IF) detection and characterization of circulating tumor cells (CTC) from men with castrate-resistant prostate cancer (CRPC) by Szmulewitz, R. Z., Wyche, A. J., Posadas, E. M., Stadler, W. M.

“…Abstract only 41 Background: Men with progressive CRPC have identifiable CTC. The currently available technologies for isolation of these CTC are limited by…”
Get full text

A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC) by Szmulewitz, R. Z., Posadas, E. M., Manchen, B., Stadler, W. M.

“…Abstract only…”
Get full text

Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES by Stenzl, A., Shore, N.D., Villers, A., Iguchi, T., Gomez-Veiga, F., Alcaraz, A., Alekseev, B., Azad, AA, Szmulewitz, RZ, Petrylak, D., Holzbeierlein, J., Rosbrook, B., Zohren, F., Haas, G.P., Gourgioti, G., El-Chaar, N.N., Armstrong, A.J.

Get full text

Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study by Ryan, C. J., Harzstark, A. L., Lin, A. M., Fong, L., Grycz, K., Szmulewitz, R. Z., Weinberg, V. K., Molina, A., Small, E. J.

“…Abstract only…”
Get full text

The incidence of potential medication interactions including herbs and supplements among breast and prostate cancer patients during and after systemic anticancer therapy by Kwon, N., Lee, R. T., Ray, M., Szmulewitz, R. Z., Von Roenn, J. H., Stadler, W. M., Curlin, F. C.

“…Abstract only…”
Get full text

A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consortium study by Ward, J. E., Limvorasak, S., Karrison, T., Chatta, G. S., Hussain, M., Shevrin, D. H., Szmulewitz, R. Z., Stadler, W. M., Posadas, E. M.

“…Abstract only 170 Background: Intermittent androgen suppression (IAS) has been studied as a way of minimizing toxicity from long term androgen deprivation…”
Get full text

Abstract PD3-02: Second-generation selective glucocorticoid receptor modulators in triple-negative breast cancer by West, DC, Hosfield, DJ, Mayne, CG, Skor, MN, Styke, SC, Pierce, CF, Kocherginsky, M, Hunt, H, Fleming, GF, Szmulewitz, RZ, Tajkhorshid, E, Greene, GL, Conzen, SD

“…Abstract Triple-negative breast cancer (TNBC) lacks expression of the estrogen receptor (ER), progesterone receptor (PR), and HER2. A subset of primary TNBCs…”
Get full text

Sequential phase II studies for endometrial cancer (EC): Pegylated liposomal doxorubicin (LD) with either paclitaxel (P) or docetaxel (D) by Szmulewitz, R. Z., Chang, R. Y., Blank, S. V., Curtin, J. P., Hochster, H. S., Hamilton, A. L., Hornreich, G., Muggia, F. M.

“…Abstract only…”
Get full text

Antiandrogen therapy in prostate cancer by Szmulewitz, Russell Z., Posadas, Edwin M.

“…Antiandrogens are an important class of therapeutic agents for treatment of prostate cancer. While traditionally used as a second-line hormonal therapy…”
Get full text